Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O, Venkataramanan R, Elens L, Moes DJAR, Hesselink DA, Pawinski T, Johnson-Davis KL, De Winter BCM, Pattanaik S, Brunet M, Masuda S, Langman LJ. Lemaitre F, et al. Among authors: brunet m. Ther Drug Monit. 2023 Apr 1;45(2):191-199. doi: 10.1097/FTD.0000000000001014. Ther Drug Monit. 2023. PMID: 35944126 Free article.
Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
Martinez-Rebollar M, Lonca M, Perez I, Soy D, Brunet M, Martin R, Coll O, Hernandez S, Laguno M, Milinkovic A, Larrousse M, Calvo M, Blanco JL, Martínez E, Gatell JM, Mallolas J. Martinez-Rebollar M, et al. Among authors: brunet m. Ther Drug Monit. 2011 Dec;33(6):772-7. doi: 10.1097/FTD.0b013e318236376d. Ther Drug Monit. 2011. PMID: 22105596
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M, Muñoz A, Pérez I, Hidalgo S, Brunet M, Laguno M, González A, Calvo M, Loncà M, Blanco JL, Martínez E, Gatell JM, Mallolas J. Martínez-Rebollar M, et al. Among authors: brunet m. Ther Drug Monit. 2013 Aug;35(4):552-6. doi: 10.1097/FTD.0b013e31828d50ef. Ther Drug Monit. 2013. PMID: 23851911
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation.
Brunet M, Shipkova M, van Gelder T, Wieland E, Sommerer C, Budde K, Haufroid V, Christians U, López-Hoyos M, Barten MJ, Bergan S, Picard N, Millán López O, Marquet P, Hesselink DA, Noceti O, Pawinski T, Wallemacq P, Oellerich M. Brunet M, et al. Ther Drug Monit. 2016 Apr;38 Suppl 1:S1-20. doi: 10.1097/FTD.0000000000000287. Ther Drug Monit. 2016. PMID: 26977997 Review.
Therapeutic Drug Monitoring of Everolimus: A Consensus Report.
Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, Brunet M, Budde K, Barten MJ, De Simone P, Wieland E, López OM, Masuda S, Seger C, Picard N, Oellerich M, Langman LJ, Wallemacq P, Morris RG, Thompson C, Marquet P. Shipkova M, et al. Among authors: brunet m. Ther Drug Monit. 2016 Apr;38(2):143-69. doi: 10.1097/FTD.0000000000000260. Ther Drug Monit. 2016. PMID: 26982492
Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee.
Seger C, Shipkova M, Christians U, Billaud EM, Wang P, Holt DW, Brunet M, Kunicki PK, Pawiński T, Langman LJ, Marquet P, Oellerich M, Wieland E, Wallemacq P. Seger C, et al. Among authors: brunet m. Ther Drug Monit. 2016 Apr;38(2):170-89. doi: 10.1097/FTD.0000000000000269. Ther Drug Monit. 2016. PMID: 26982493 Review.
Pharmacodynamic Monitoring of mTOR Inhibitors.
Millán O, Wieland E, Marquet P, Brunet M. Millán O, et al. Among authors: brunet m. Ther Drug Monit. 2019 Apr;41(2):160-167. doi: 10.1097/FTD.0000000000000616. Ther Drug Monit. 2019. PMID: 30883509 Review.
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Brunet M, et al. Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640. Ther Drug Monit. 2019. PMID: 31045868 Review.
Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel.
Lemaitre F, Vethe NT, D'Avolio A, Tron C, Robertsen I, De Winter B, Denicolo A, Koch BCP, Venkataramanan R, Van Gelder T, Brunet M, Bergan S, Hesselink DA, Wallemacq P. Lemaitre F, et al. Among authors: brunet m. Ther Drug Monit. 2020 Oct;42(5):665-670. doi: 10.1097/FTD.0000000000000780. Ther Drug Monit. 2020. PMID: 32520841
596 results